Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    Melrose Industries

    MCap

    GBP8,832m

    Last close

    GBP6.70

    ▲ 74.80 (12.57%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

OSE Immunotherapeutics (PAR: OSE)

Last close As at 17/04/2024

EUR4.65

▲ 0.04 (0.76%)

Market capitalisation

EUR102m

OSE Immunotherapeutics (OSE) is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

OSE has products in development for both immunoncology and immuno-inflammation indications. As a result, the R&D pipeline is diversified and the outlook does not depend on developments in any specific subsector.

Latest Insights

View More

Healthcare | Flash note

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development

Healthcare | Update

OSE Immunotherapeutics — Pipeline momentum builds into FY24

Healthcare | Flash note

OSE Immunotherapeutics — One step closer to key data readouts

Healthcare | Flash note

OSE Immunotherapeutics — Confidence boost with AbbVie partnership
OSE-Immunotherapeutics_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dominique Costantini

    Chairman

  • Nicolas Poirier

    CEO

Balance Sheet

Forecast net cash (€m)

5.4

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.1) 24.7 (6.1)
Relative (0.6) 16.8 (10.3)
52 week high/low €6.2/€2.7

Financials

Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public funding from Bpifrance (a French public sector financing institution). Proceeds will be directed to support the upcoming registrational Phase III study of lead asset Tedopi, in second-line treatment in HLA-A2 positive non-small cell lung cancer (NSCLC) patients with secondary (acquired) resistance to anti-PD-(L)1 immunotherapy. This announcement follows the company’s $713m deal with AbbVie, reported in February, for preclinical asset OSE-230 (in chronic inflammation). Bpifrance in Q223 had granted €1.5m in non-dilutive funding to support the development of a companion diagnostic screening test to help identify HLA-A2 positive NSCLC patients, who have a higher likelihood of responding to Tedopi.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2022A 18.3 (15.0) (18.0) (97.28) N/A N/A
2023A 2.2 (19.6) (23.2) (118.70) N/A N/A
2024E 56.9 28.6 25.3 114.54 4.1 4.1
2025E 65.5 36.9 33.7 149.02 3.1 3.1

Research

Update

Healthcare

OSE Immunotherapeutics — Pipeline momentum builds into FY24

Flash note

Healthcare

OSE Immunotherapeutics — One step closer to key data readouts

Healthcare

Flash note

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free